Definitive Healthcare Corp. (DH) - 10-K Summary
Business Context and Reporting Period
Company: Definitive Healthcare Corp.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Definitive Healthcare is a leading provider of healthcare commercial intelligence via a SaaS platform. It aggregates data on healthcare providers, services, and consumers to assist Life Sciences, Provider, and Diversified customers in go-to-market planning and sales execution. As of December 31, 2025, the company served approximately 2,330 customers.
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | $241.5 | $252.2 | $251.4 |
| Gross Profit | $183.3 | $197.5 | $203.9 |
| Gross Margin | 76% | 78% | 81% |
| Net Loss (GAAP) | $(199.3) | $(591.4) | $(289.6) |
| Net Loss Attributable to DH Corp. | $(138.9) | $(413.1) | $(202.4) |
| Adjusted EBITDA | $70.4 | $79.1 | $74.5 |
| Adjusted EBITDA Margin | 29% | 31% | 30% |
| Cash & Cash Equivalents | $163.6 | $105.4 | $131.0 |
| Short-Term Investments | $17.3 | $184.8 | $131.0 |
| Total Debt (Principal) | $166.3 | $244.1 | N/A |
| Goodwill (Net) | $197.2 | $393.3 | $1,075.1 |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 4% year-over-year to $241.5 million, driven by a $12.7 million decrease in subscription revenue. This was partially offset by a $2.0 million increase in professional services revenue. Management attributes the decline to macroeconomic headwinds, sales execution challenges following a 2024 restructuring, and lower renewal rates.
- Goodwill Impairment: The company recorded a non-cash goodwill impairment charge of $196.1 million in 2025, a significant reduction from the $688.9 million charge in 2024. This reduction was the primary driver for the improvement in GAAP net loss.
- Operating Expenses: Total operating expenses decreased 55% to $407.5 million, largely due to the lower goodwill impairment charge. Excluding impairment, operating expenses remained relatively stable, with slight decreases in sales and marketing and product development due to headcount reductions.
- Liquidity: Cash and cash equivalents increased to $163.6 million, while short-term investments decreased significantly to $17.3 million as maturities were realized. The company repaid $77.8 million of its term loan principal in 2025.
Guidance, Outlook, and Risks
- Outlook: Management expects revenue to decline in 2026 compared to 2025. This projection is based on continued macroeconomic challenges, elongated deal cycles, and pressures on renewals. Current Remaining Performance Obligations (cRPO) decreased to $165.1 million from $188.1 million in the prior year.
- Key Risks:
- Macroeconomic Conditions: Difficult economic conditions have led to longer sales cycles, deferred purchasing decisions, and heightened churn, particularly among smaller customers and in the Life Sciences sector.
- Goodwill Impairment: The company remains at risk for future goodwill impairments if market capitalization continues to decline or macroeconomic conditions worsen.
- Data Access: The company relies on third-party data providers. Disruptions or increased costs from these providers could negatively impact the platform and margins.
- Legal Proceedings: The company is engaged in litigation regarding the earn-out calculation for its 2023 acquisition of Populi, Inc. Management disputes the former equity holders' claim for additional consideration.
- Management Commentary: Late in 2025, the company observed modest signs of improvement, including healthier demand trends and more normalized procurement cycles. However, the company expects these trends to continue impacting growth into 2026.
Investor Verification Checklist
- Revenue Trajectory: Verify the sustainability of the revenue decline and the specific impact of the "sales execution challenges" mentioned in the MD&A on future bookings.
- Goodwill Valuation: Review the assumptions used in the goodwill impairment test, specifically the control premium and market capitalization inputs, to assess the risk of further impairments.
- Customer Churn & Retention: Analyze the Net Dollar Retention (NDR) rate, which dropped to 81% in 2025 from 85% in 2024, and the specific churn rates in the Life Sciences segment.
- Debt Covenants: Confirm compliance with the maximum total leverage ratio covenant under the 2021 Credit Agreement, especially given the revenue decline.
- Populi Litigation: Monitor the status of the dispute regarding the Populi earn-out, as a loss could result in additional contingent consideration liabilities.
- Data Costs: Assess the impact of renegotiated data contracts and the exit of a major data contract on future cost of revenue and gross margins.